XBiotech Inc (XBIT.OQ)
XBIT.OQ on NASDAQ Stock Exchange Global Select Market
4.33USD
20 Jul 2018
4.33USD
20 Jul 2018
Change (% chg)
$-0.05 (-1.14%)
$-0.05 (-1.14%)
Prev Close
$4.38
$4.38
Open
$4.39
$4.39
Day's High
$4.44
$4.44
Day's Low
$4.30
$4.30
Volume
12,067
12,067
Avg. Vol
33,971
33,971
52-wk High
$5.80
$5.80
52-wk Low
$3.55
$3.55
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Mar '18 | 0.00 | -0.115 |
| FY 2017 | Dec '17 | 0.00 | -0.224 |
| Sep '17 | 0.00 | -0.175 | |
| Jun '17 | 0.00 | -0.259 | |
| Mar '17 | 0.00 | -0.317 | |
| FY 2016 | Dec '16 | 0.00 | -0.504 |
| Sep '16 | 0.00 | -0.385 | |
| Jun '16 | 0.00 | -0.421 | |
| Mar '16 | 0.00 | -0.318 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago |
|---|
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 214.53 | 33.05 | |
| P/E High - Last 5 Yrs. | -- | 284.38 | 47.17 | |
| P/E Low - Last 5 Yrs. | -- | 96.91 | 24.95 | |
| Beta | -- | 0.76 | 0.81 | |
| Price to Sales (TTM) | -- | 254.39 | 8.10 | |
| Price to Book (MRQ) | 2.76 | 21.00 | 4.20 | |
| Price to Tangible Book (MRQ) | 2.71 | 27.24 | 6.22 | |
| Price to Cash Flow (TTM) | -- | 130.02 | 22.23 | |
| % Owned Institutions | -- | 0.00 | 0.00 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.36 | 1.74 | |
| Dividend Yield - 5 Year Avg | -- | 0.21 | 1.46 | |
| Dividend 5 Year Growth Rate | -- | 2.25 | -6.34 | |
| Payout Ratio(TTM) | -- | 83.66 | 47.29 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 33.06 | 4.76 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 147.32 | 12.20 | |
| Sales - 5 Yr. Growth Rate | -- | 30.74 | 7.68 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 63.82 | -78.41 | 49.25 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 52.50 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 46.75 | 7.98 | |
| Capital Spending - 5 Yr. Growth Rate | 20.63 | 42.59 | 7.61 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.72 | 2.56 |
| Current Ratio (MRQ) | 12.22 | 6.63 | 3.63 |
| LT Debt to Equity (MRQ) | 0.00 | 24.37 | 13.18 |
| Total Debt to Equity (MRQ) | 0.00 | 28.57 | 17.32 |
| Interest Coverage (TTM) | -187.85 | -156.06 | 35.18 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 55.96 | 55.27 | |
| Gross Margin - 5 Yr. Avg. | -- | 53.49 | 53.21 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -- | -180.79 | 15.63 | |
| Operating Margin (TTM) | -- | -952.42 | -0.59 | |
| Operating Margin - 5 Yr. Avg. | -- | -194.47 | 10.78 | |
| Pre-Tax Margin (TTM) | -- | -846.49 | 1.29 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | -199.31 | 10.90 | |
| Net Profit Margin (TTM) | -- | -837.92 | -2.01 | |
| Net Profit Margin - 5 Yr. Avg. | -- | -197.08 | 7.26 | |
| Effective Tax Rate (TTM) | -- | 14.85 | 20.80 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 19.02 | 24.29 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 0 | 23,390,416 | 736,883,287 | |
| Net Income/Employee (TTM) | -522,667 | -1,131,911 | 85,936,826 | |
| Receivable Turnover (TTM) | -- | 17.85 | 5.95 | |
| Inventory Turnover (TTM) | -- | 2.85 | 3.69 | |
| Asset Turnover (TTM) | 0.00 | 0.48 | 0.87 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -36.40 | -2.22 | 10.35 | |
| Return on Assets - 5 Yr. Avg. | -54.33 | 2.95 | 11.02 | |
| Return on Investment (TTM) | -38.43 | -3.67 | 13.17 | |
| Return on Investment - 5 Yr. Avg. | -58.46 | 2.77 | 14.24 | |
| Return on Equity (TTM) | -38.44 | -5.61 | 15.10 | |
| Return on Equity - 5 Yr. Avg. | -58.48 | -4.39 | 15.57 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | 41.62 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for XBiotech Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 1.15 | -0.82 | 63 | 39 |
| 13 Week | -9.50 | -13.10 | 34 | 61 |
| 26 Week | -2.88 | -3.11 | 54 | 70 |
| 52 Week | -15.28 | -25.27 | 43 | 84 |
| YTD | 11.17 | 5.98 | 64 | 85 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-XBiotech Announces First Patient In Phase 2 Study Evaluating Patients With Atopic Dermatitis
- BRIEF-XBiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology
- BRIEF-Xbiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology
- BRIEF-XBiotech In-Licenses Anti-NY-ESO 1 Antibody Targeting Advanced Cancer
Institutional Holders
| % Shares Owned: | 15.17% |
| # of Holders: | 65 |
| Total Shares Held: | 5,388,061 |
| 3 Mo. Net Change: | -5,421 |
| # New Positions: | 0 |
| # Closed Positions: | 1 |
| # Increased Positions: | 1 |
| # Reduced Positions: | 1 |
| # Net Buyers: | 0 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.